Truist Securities Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $31
Portfolio Pulse from jenniferd'souza@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI), but has lowered the price target from $71 to $31.
August 15, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $71 to $31, Truist Securities maintains a 'Buy' rating on BioXcel Therapeutics.
The news is directly related to BioXcel Therapeutics and is likely to impact its stock price. The 'Buy' rating indicates positive sentiment, but the significant reduction in price target may cause some uncertainty among investors, potentially leading to short-term volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100